Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Irinotecan hydrochloride trihydrate

Copy Product Info
🥰Excellent
Catalog No. T0486Cas No. 136572-09-3
Alias Irinotecan HCl Trihydrate, CPT-11 HCl Trihydrate

Irinotecan hydrochloride trihydrate (CPT-11 HCl Trihydrate) keeps DNA from unwinding by inhibiting topoisomerase 1.

Irinotecan hydrochloride trihydrate

Irinotecan hydrochloride trihydrate

Copy Product Info
🥰Excellent
Purity: 99.79%
Catalog No. T0486Alias Irinotecan HCl Trihydrate, CPT-11 HCl TrihydrateCas No. 136572-09-3
Irinotecan hydrochloride trihydrate (CPT-11 HCl Trihydrate) keeps DNA from unwinding by inhibiting topoisomerase 1.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
25 mg$36In StockIn Stock
50 mg$52In StockIn Stock
100 mg$72In StockIn Stock
200 mg$96In StockIn Stock
500 mg$162In StockIn Stock
1 mL x 10 mM (in DMSO)$57In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.79%
Color:White to Yellow
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
Irinotecan hydrochloride trihydrate (CPT-11 HCl Trihydrate) keeps DNA from unwinding by inhibiting topoisomerase 1.
In vitro
In the liver, stomach, duodenum, and colon, a single dose of Irinotecan significantly increases the covalent binding of topoisomerase I to DNA. Compared to the control group, there is a marked increase in DNA strand breaks within the colonic mucosal cells in the Irinotecan-treated group. In COLO320 xenografts, Irinotecan induces a 92% maximum growth inhibition.
In vivo
In LoVo and HT-29 cell lines, Irinotecan induces a similar number of cleavable complexes at IC50 concentrations, with no significant difference observed between the two. The formation of cleavable complexes by SN-38 is concentration-dependent and consistent across both cell lines. Notably, intracellular accumulation of Irinotecan differs significantly, with consistently higher levels in HT-29 cells compared to LoVo cells. Carboxylesterase activation of Irinotecan to SN-38 (primarily in the liver) facilitates interaction with its target, topoisomerase I, in plasma, intestines, and tumor tissues. The hydrolysis of Irinotecan’s lactone E-ring and SN-38 is reversible in aqueous solution, with the interconversion of their carboxylate and lactone forms dependent on temperature and pH. For the same concentration of SN-38 glucuronide and Irinotecan in tumor and normal tissues, the yield of SN-38 via β-glucuronidase mediation exceeds that of SN-38 produced from Irinotecan. In SCLC cell lines, Irinotecan exhibits markedly greater activity than in NSCLC cell lines, while tissue histology does not reveal significant differences in SN-38 efficacy.
Cell Research
Exponentially growing cells (LoVo and HT-29 cells) are seeded in 20 cm2 Petri dishes with an optimal cell number for each cell line (2 × 104 for LoVo cells, 105 for HT-29 cells). They are treated 2 days later with increasing concentrations of Irinotecan or SN-38 for one cell doubling time (24 hours for LoVo cells, 40 hours for HT-29 cells). After washing with 0.15 M NaCl, the cells are further grown for two doubling times in normal medium, detached from the support with trypsin-EDTA and counted in a hemocytometer. The IC50 values are then estimated as the Irinotecan or SN-38 concentrations responsible for 50% growth inhibition as compared with cells incubated without Irinotecan or SN-38. (Only for Reference)
SynonymsIrinotecan HCl Trihydrate, CPT-11 HCl Trihydrate
Chemical Properties
Molecular Weight677.18
FormulaC33H45ClN4O9
Cas No.136572-09-3
SmilesO.O.O.Cl.CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12
Relative Density.no data available
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
H2O: 1 mg/mL (1.48 mM), Sonication is recommended.
Ethanol: 7 mg/mL (10.34 mM), Sonication is recommended.
DMSO: 45 mg/mL (66.45 mM), Sonication is recommended.
In Vivo Formulation
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (2.95 mM), Sonication is recommended.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
H2O/Ethanol/DMSO
1mg5mg10mg50mg
1 mM1.4767 mL7.3836 mL14.7671 mL73.8356 mL
Ethanol/DMSO
1mg5mg10mg50mg
5 mM0.2953 mL1.4767 mL2.9534 mL14.7671 mL
10 mM0.1477 mL0.7384 mL1.4767 mL7.3836 mL
DMSO
1mg5mg10mg50mg
20 mM0.0738 mL0.3692 mL0.7384 mL3.6918 mL
50 mM0.0295 mL0.1477 mL0.2953 mL1.4767 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Irinotecan hydrochloride trihydrate | purchase Irinotecan hydrochloride trihydrate | Irinotecan hydrochloride trihydrate cost | order Irinotecan hydrochloride trihydrate | Irinotecan hydrochloride trihydrate chemical structure | Irinotecan hydrochloride trihydrate in vivo | Irinotecan hydrochloride trihydrate in vitro | Irinotecan hydrochloride trihydrate formula | Irinotecan hydrochloride trihydrate molecular weight